DexCom, Inc. cash flow to debt ratio of 103.67% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

DexCom, Inc.'s free cash flow has increased 70.79% from $630.70M last year to $1.08B, signaling increasing performance

DexCom, Inc.'s debt to equity ratio is 0.53, which means that the company's assets are healthy financed, signaling financial stability.

DexCom, Inc.'s debt has decreased relative to shareholder equity from 1.23 last year to 0.53 today, signaling strengthened financials

DexCom, Inc. has a net cash position, so leverage is healthy.

DexCom, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

DexCom, Inc.'s profit margin has increased (40.81%) in the last year from 14.29% to 20.12%, signaling increasing performance

DexCom, Inc.'s short-term assets of $4.03B exceed its short-term liabilities of $2.14B

DexCom, Inc.'s return on assets of 15.49% is higher than the 5.00% threshold, indicating efficient asset utilization

DexCom, Inc.'s return on equity of 36.19%, is higher than 15.00%, indicating good performance

DexCom, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

DexCom, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

DexCom, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

DexCom, Inc. has a free cash flow yield of 3.26%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

DexCom, Inc.'s yearly earnings has increased 45.14% since last year from $576.20M to $836.30M, signaling increasing performance

DexCom, Inc.'s yearly revenue has increased 15.60% since last year from $4.03B to $4.66B, signaling increasing performance

ROIC 21.60% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

DexCom, Inc.'s 3-year revenue CAGR of 17.01% is positive, indicating growing revenue over the past 3 years

DexCom, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

DexCom, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

DexCom, Inc. is overvalued relative to its fair value price of 47.82 based on Discounted Cash Flow model

DexCom, Inc. has an earnings yield of 2.97%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

DexCom, Inc. is overvalued relative to its fair value price of 19.68 based on EBITDA multiple model

DexCom, Inc. has an EV/EBITDA ratio of 23.90x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

DexCom, Inc. is overvalued relative to its fair value price of 32.63 based on Earnings Fair Value model

DexCom, Inc. has a PEG-ratio over 1 which is considered overvalued

DexCom, Inc. has a price-to-book ratio of 12.83x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

DexCom, Inc. has a price-to-sales ratio of 6.77x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue